24584-09-6
Chemical Structure
Dexrazoxane
Synonym(s): ICRF-187; ADR-529; NSC-169780
- CAS 番号: 24584-09-6
- Formula:C11H16N4O4
- Molecular Weight:268.27
IUPAC Name: (S)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)
InChIKey: BMKDZUISNHGIBY-ZETCQYMHSA-N
SMILES: C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
Biological Activity: Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells[1] [2] [3] [4] [5] [6].
| 製品番号 | 製品名 | 純度 | 製品説明 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dexrazoxane | 99.88% | Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Dexrazoxane (Standard) | ≥98% | Dexrazoxane (Standard) is the analytical standard of Dexrazoxane. This product is intended for research and analytical applications. Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells . | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Rahimi P, et al. Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines. Cureus. 2023 Apr 8;15(4):e37308. [Content Brief]
- [2]. Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007 Jul;151(6):771-8. [Content Brief]
- [3]. de Baat EC, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022 Dec;6(12):885-894. [Content Brief]
- [4]. Deng S, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172(9):2246-57. [Content Brief]
- [5]. Zhang H, et al. Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021 Jul 14;8:685434. doi: 10.3389/fcvm.2021.685434. [Content Brief]
- [6]. Mei M, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1;160:107758. [Content Brief]
Keywords
